Pfizer and Allergan will have to scrap the merger deal following the new regulation from Treasury Department to stop the U.S. company moving overseas.
Bio Tech
US Study Discovers 275 Million New Genetic Variants That Can Significantly Improve Drug Development
A new study that examined the genetic code of nearly 250,000 volunteers in the US found over 275 million entirely new variants.
Goldman Sachs Identifies 2 Healthcare Stocks With up to 130% Upside Potential
Goldman Sachs has identified two healthcare stocks with the potential for substantial gains, reaching up to 130%.
Regulatory Compliance in Biologics CDMO: Meeting the Standards
Contract Development and Manufacturing Organizations (CDMOs) involved in biologics production must adhere to stringent regulatory standards set forth by regulatory authorities such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This article aims to provide an overview of regulatory compliance in biologics CDMOs, highlighting the key standards and best practices that these organizations need to follow.
Consumer Products, Healthcare Leads The Tuesday Sectors
The growing demand for Consumer Products, Healthcare sectors to lead for Tuesday. Each day, millions of people of all ages in homes around the world use products from one or more of our consumer health care companies.
Latest News
BioPen uses 3D bioprinting technology to enable surgeons draw viable human stem cells in order to reconstruct bones of damaged joints. The product is still at the R&D stage and is still being actively tested and improved.
Shares of the German pharmaceutical and chemical giant increased by 5% in Monday trading. Monsanto's interest to acquire its crop science business triggered the surge.
Duke Energy will buy biogas produced from swine and poultry wastes. The biogas will then be converted to electricity that could power up about 10,000 homes yearly. Duke Energy works with Carbon Cycle Energy to make the project successful.
Celator Pharmaceuticals shares jumped more than 400% in Tuesday trading. Meanwhile, hedge fund manager Steve Cohen unvelied his 8.3% shares of the company.
Drug maker Valeant Pharmaceuticals International Inc is facing a variety of problems. Valeant has changed its aggressive investment strategy and turned keen on research and development. Valeant is also facing Federal investigation over its pricing strategies.
The Canadian drugmaker on Wednesday announced to add three new directors to its board. Representative from Pershing Square Capital Management was added as one of the directors.
Visikol Inc is a biotech company with focused on tissue visualization. On Tuesday, the company has secured a commitment from Foundation Venture Capital Group
The Series A round was announced on Wednesday. The company has also licensed the rights for multiple immuno-oncology programs from Stanford University.
Led by technology sector, venture capital (VC) investments in Canada reached 10 year high in 2015. Canadian Venture Capital & Private Equity Association (CVCA) said 536 deals in funding for entrepreneurs raised $2.25 billion in 2015.
